Endogenous ouabain, sodium balance and blood pressure: A review and a hypothesis

Journal of Hypertension

Volumn 14, Issue 2, 1996, Pages 151-167

  Hamlyn, John M ^a   Hamilton, Bruce P ^a   Manunta, Paolo ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Adrenal tumour; Angiotensin II; Cardiac glycosides; Congestive heart failure; Digitalis like; Digoxin; Extracellular fluid volume; Renal failure; Sodium potassium pump; Steroids

Indexed keywords

OUABAIN; SODIUM;

ADRENAL GLAND; ADRENERGIC ACTIVITY; BLOOD PRESSURE; ELECTROLYTE BALANCE; FLUID BALANCE; HUMAN; HYPERTENSION; HYPOPHYSIS; HYPOTHALAMUS; KIDNEY; NONHUMAN; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; REVIEW; SODIUM BALANCE; SODIUM URINE LEVEL;

ADRENAL GLAND NEOPLASMS; ANIMALS; BLOOD PRESSURE; BRAIN; CARDIOTONIC AGENTS; HUMANS; HYPERTENSION; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; RATS; SODIUM; WATER-ELECTROLYTE BALANCE;

EID: 0029880847     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199602000-00002     Document Type: Review

References (136)

1. Arnaud A: Sur la matilère cristallisée active de flèches empoisonnées des Comalis, extraite du bois d'Ouabalo. Compte Rend Acad Sci Paris 1988, 106:1011-1014.
2. Pidgeon GB, Lewis LK, Yandle TG, Richards AM, Nicholls MG: Endogenous ouabain, sodium balance and blood pressure [commentary]. J Hypertens 1996, 14:169-171.
3. Goto A, Yamada K, Yagi N, Yoahika M, Sugimoto T: Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992, 44:377-399.
4. Graves SW: Endogenous digitalis-like factors. CRC Crit Rev Clin Lab Sci 1986, 23:177-200.
5. Hamlyn JM, Harris DW, Ludens JH: Digitalis-like activity in human plasma: purification, affinity and mechanism. J Biol Chem 1989, 264:7395-7404.
6. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, et al.: Mass spectral characterization of an endogenous digitalislike factor from human plasma. Hypertension 1991, 17:930-935.
7. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, et al.: Identification and characterization of a ouabain-like compound from human plasma Proc Natl Acad Sci USA 1991, 88:6259-6263.
8. Ludens JH, Clark MS, DuCharme DW, Harris DW, Lutzke BS, Mandel F, et al.: Purification of an endogenous digitalislike factor for structural analysis. Hypertension 1991, 17:923-929.
9. Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, Hamlyn JM: Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension 1991, 17:944-950.
10. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, et al.: Development of an immunoassay for endogenous digitalis-like factor. Hypertension 1991, 17:936-943.
11. Huang BS, Harmsen E, Yu H, Leenen F: Brain ouabain-like activity and the sympathoexcitatory and pressor effects of central sodium in rats. Circ Res 1992, 71:1059-1086.
12. Kuske R, Moreth K, Renner D, Wizemann V, Schoner W: Sodium pump inhibitor In the serum of patients with essential hypertension and its partial purification from hemofiltrate. Klin Wochenschr 1987, 65 (suppl 8):53-59.
13. Goto A, Yamada K, Ishii M, Sugimoto T: Digitalis-like activity in human plasma: relation to blood pressure and sodium balance. Am J Med 1990, 89:420-426.
14. Delva P, Capra C, Degan M, Minuz P, Covi G, Milan L, et al.: High plasma levels of a ouabain-like factor in normal pregnancy in pre-eclampsia. Eur J Clin Invest 1989, 19:95-100.
15. Delva P, Degan M, Capra C, Fallo F, Mantero F, Menegazzi M, et al.: Plasma ouabain-like activity in essential hypertensive patients and In subjects with primary aldosteronism. Min Elect Metab 1989, 15:315-320.
16. Sandor T, Idler DR: Steroid methodology. In Steroids in Nonmammalian Vertebrates. Edited by Idler DR. New York: Academic Press; 1972:6-36.
17. Laredo J, Hamilton BP, Hamlyn JM: Ouabain is secreted by bovine adrenocortical cells. Endocrinology 1994, 135:794-797.
18. Hamlyn JM: Discovery of endogenous oubain - a new mammalian hormone. In The Sodium Pump, Structure, Mechanism, Hormonal Control and Role in Disease. Proceedings of the VIIth International Conference on the Sodium Pump. Todtmoos, Germany, September 5-11, 1993. Edited by Bamberg E, Schoner W. New York: Springer; 1994:722-731.
19. Tamura M, Konishi F, Sakakibara M, Inagami T: Large scale purification of an endogenous Na/K-pump Inhibitor from bovine adrenal glands. In The Sodium Pump, Structure, Mechanism, Hormonal Control and Role in Disease. Proceedings of the VIIth International Conference on the Sodium Pump. Todtmoos, Germany, September 5-11, 1993. Edited by Bamberg E, Schoner W. New York: Springer; 1994:763-766.
20. Tymiak AA, Norman JA, Bolgar M, DiDonato GC, Lee H, Parker WL, et al.: Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci USA 1993, 90:8189-8193.
21. Zhao N, Lo L-C, Berova N, Nakanishi K, Tymiak AA, Ludens JH, et al.: ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: nanogram scale CD structural analysis. Biochemistry 1995, 34:9893-9896.
22. Carilli CT, Berne M, Cantley LC, Haupert GT Jr: Hypothalamic factor inhibits the Na/K-ATPase from the extracellular surface. J Biol Chem 1985, 260:1027-1031.
23. Hallaq HA, Haupert GT: Positive inotropic effects of the endogenous Na,K transporting ATPase inhibitor from the hypothalamus. Proc Natl Acad Sci USA 1989, 86:10080-10084.
24. Haupert GT: Structure and biological activity of the Na/K- ATPase Inhibitor Isolated from bovine hypothalamus: difference from ouabain. In The Sodium Pump, Structure, Mechanism, Hormonal Control and Role in Disease. Proceedings of the VIIth International Conference on the Sodium Pump. Todtmoos, Germany, September 5-11, 1993. Edited by Bamberg E, Schoner W. New York: Springer; 1994:32-742.
25. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM: Ouabain- Induced hypertension in the rat: relationships among circulating and tissue ouabain and blood pressure. J Hypertens 1994, 12:549-560.
26. Pernollet MG, Ali RM, Meyer P, Devynck M-A: Are the circulating digitalis-like compounds of adrenal origin? J Hypertens 1986, 4 (suppl 6):S382-S384.
27. Gomez-Sanchez E, Foeking MF, Sellers D, Blankenship MS, Gomez-Sanchez CE: Is the circulating ouabain-like compound ouabain? Am J Hypertens 1994, 7:647-650.
28. Doris PA, Jenkins LA, Stocco DM: Is ouabain an authentic endogenous mammalian substance derived from the adrenal? Hypertension 1994, 23:632-638.
29. Doris PA: Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 1994, 266:H360-H364.
30. Pidgeon GB, Richards AM, Nicholls MG, Lewis LK, Yandle TG: Acute effects of intravenous ouabain in healthy volunteers. Clin Sci Colch 1994, 86:391-397.
31. Lewis L, Yandle TG, Lewis JG, Richards AM, Pidgeon GB, Kaaja RJ, et al.: Ouabain Is not detectable in human plasma. Hypertension 1994, 24:549-555.
32. Hamlyn JM, Manunta P: Ouabain, digitalis-like factors and hypertension. J Hypertens 1992, 10 (suppl 7):S99-S111.
33. de Wordener HE, Mills IH, Clapham WF, Hayter CJ: Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci Colch 1961, 21:249-258.
34. Alaghband-Zadeh J, Fenton S, Hancock K, Millett J, de Wardener HE: Evidence that the hypothalamus may be the source of a circulating Na,K-ATPase inhibitor. J Endocrinol 1983, 98:221-226.
35. deWardener HE, MacGregor GA: The role of a circulating inhibitor of Na,K-ATPase in essential hypertension. Am J Nephrol 1983, 3:88-91.
36. deWardener HE, MacGregor GA: Dahl's hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: its possible role in essential hypertension. Kidney Int 1980, 18:1-9.
37. Hamlyn JM, Ludens JH: Non-atrial natriuretic hormones. In The Kidney, Physiology and Pathophysiology, 2nd Edn. Edited by Seldin D, Giebisch G. New York: Raven Press; 1992:1885-1924.
38. Siperstein MD, Murray AW, Titus E: Biosynthesis of cardiotonic steroids from cholesterol in the toad, Bufo marinus. Arch Biochem Biophys 1957, 67:154-160.
39. Lichtstein D, Kachalsky S, Deutsch J: Identification of a ouabain-like compound in toad chrysomelid beetles. Experientia 1987, 43:460-462.
40. Van Oycke S, Braekman JC, Daloze D, Pasteels JM: Cardenolide biosynthesis in chrysomelid beetles. Experientia 1987, 43:460-462.
41. Hyman AL, Jaques WE, Hyman ES: Observation on the direct effect of digoxin on renal excretion of sodium and water. Am Heart J 1956, 52:592-608.
42. Strickler JC, Kessler RH: Direct renal actions of some digitalis steroids. J Clin Invest 1961, 40:311-316.
43. Lloyd MA, Sandberg SM, Edwards BS: Role of renal Na,K-ATPase in the regulation of sodium excretion under normal conditions and in congestive heart failure. Circulation 1992, 85:1912-1917.
44. Hook JB: A positive correlation between natriuresis and inhibition of renal Na,K-adenosine triphosphatase by ouabain. Proc Soc Biol Med 1969, 131:731-734.
45. Pamnani MB, Chen S, Bryant HJ, Schooley JF Jr, Eliades DC, Yuan CM, et al.: Effects of three sodium-potassium adenosine triphosphatase inhibitors. Hypertension 1991, 18:316-324.
46. Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS: Ouabain is secreted by the adrenal gland in awake dogs. Am J Physiol 1993, 264:E413-E419.
47. Ludens JH, Clark M, Kolbasa K, Hamlyn JM: Digitalis-like factor and ouabain like compound in the plasma of volume expanded dogs. J Cardiovasc Pharmacol 1993, 22 (suppl 2):S38-S41.
48. Ribner HS, Plucinski DA, Hsieh AM, Bresnahan D, Molteni A, Askenazi J, et al.: Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic hormonal study. Am J Cardiol 1985, 56:896-904.
49. Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA: The effect of oral digoxin on sodium excretion, renin-angiotensin- aldosterone system and blood pressure in normotensive subjects. Postgrad Med J 1986, 62:265-268.
50. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM: Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992, 86:420-425.
51. Masugi F, Ogihara T, Hasegawa T, Tomii A, Nagano M, Higashimori K, et al.: Circulating factor with ouabain-like immunoreactivity in patients with primary aldosteronism. Biochem Biophys Res Commun 1995, 135:41-45.
52. Donner TW, Hamilton BP Manunta P, Valente WA, Hamlyn JM: Plasma ouabain in patients with hyperthyroidism [abstract]. Proceedings of the 74th Annual Endocrine Society Meeting, San Antonio, Texas. 1992:129.
53. Schaeffer JS, Talartschik J, Koch KM, Rogowski AC, Manunta P, Hamlyn JM: Increased plasma levels of ouabain-like compound in dialysis patients: relationship with interdialytic volume changes [abstract]. J Am Soc Nephrol 1991, 2 (suppl 3):348.
54. Argento NB, Hamilton BP, Valente WA, Hamlyn JM: Increased circulating levels of a ouabain-like compound in hypothyroid hypertension [abstract]. Hypertension 1991, 18:425.
55. Naruse K, Narause M, Tanabe A, Yoshimoto T, Watanabe Y, Kurimoto F, et al.: Does plasma immunoreactive ouabain originate in adrenal gland? Hypertension 1994, 23 (suppl I):1102-1105.
56. Hohl AS, Hamilton BP, Hamlyn JM: Dynamics of intracellular calcium, endogenous digitalis and other volume-sensitive hormones during 9-alpha fluorohydrocortisone administration to normal man [abstract]. Endocrine Society Abstracts 1990, 233.
57. Rossi GP, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A, et al.: Endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure. J Hypertens 1995.
58. Manunta P, Evans G, Hamilton BP, Gann D, Resau J, Hamlyn JM: A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor [abstract]. J Hypertens 1992, 10 (suppl 4):S27.
59. Goto A, Yamada K, Yagi N, Hagoshi H, Hui C, Sugimoto T: Novel concepts on the roles of ouabain-like compound (OLC) in hypertension [abstract]. J Hypertens 1992, 10 (suppl 4):S50.
60. Masugi F, Ogihara T, Hasegawa T, Kumahara Y: Ouabain and non-ouabain-like factors in plasma of patients with essential hypertension. Clin Exp Hypertens [A] 1987, 9:1233-1242.
61. Masugi F, Ogihara T, Hasegawa T, Sakaguchi K, Kumahara Y: Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adrenals. J Hum Hypertens 1988, 2:409-420.
62. Nuitta E, Cusi D, Colombo R, Tripodi G, Pellizoni M, Patti P, et al.: Antihypertensive effect of captopril, canrenoate potassium and atenolol: relations with red blood cell sodium transport and renin. Am J Hypertens 1988, 1:364-371.
63. Canessa M, Adragna N, Solomon HS, Connolly TM, Tosteson DC: Increased sodium-lithium counter-transport in red cells of patients with essential hypertension. N Engl J Med 1980, 302:771-776.
64. Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinove S, Williams GH: Abnormal renal sodium handling in essential hypertension: relation to failure of renal and adrenal modulation of response to angiotensin II. Am J Med 1986, 81:412-418.
65. Zinner SH, Margolius HS, Rosner B, Keiser HR, Kass EH: Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 1976, 104:124-132.
66. Semplicini A, Buzzaccarini F, Ceolotto G, Marzola M, Mozzata MG, Guisto M, et al.: Effects of canrenoate on red cell sodium transport and calf flow in essential hypertension. Am J Hypertens 1993, 6:295-301.
67. Guthrie GP Jr: Effects of digoxin on responsiveness to the pressor actions of angiotensin and norepinephrine in man. J Clin Endocr Metab 1984, 58:76-80.
68. Kramer HJ, Glanzer K, Freitag T, Schonfeld J, Sorger M, Schlebusch H, et al.: Studies on the role of sodium and potassium activated adenosine triphosphatase inhibition in the pathogenesis of human hypertension. Klin Wochenschr 1984, 63:32-36.
69. Mason DT, Braunwald E: Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure. J Clin Invest 1964, 43:532-543.
70. Yamaji I, Kikuchi K, Nishimura M, Nozawa A, Hasegawa T, Kobayakawa H, et al.: The role of Na,K-ATPase inhibitor on pressor responsiveness in patients with benign essential hypertension. Am J Hypertens 1990, 3:176-181.
71. Kumar R, Yankopoulos NA, Abelman WH: Ouabain-induced hypertension in a patient with decompensated hypertensive heart disease. Chest 1973, 63:105-107.
72. Ross J, Waldhausen JA, Braunwald E: Studies on digitalis I: direct effects on peripheral vascular disease. J Clin Invest 1960, 39:930-938.
73. Yuan C, Manunta P, Hamlyn JM, Chen SW, Bohen E, Yeun J, et al.: Chronic ouabain administration produces hypertension in rats. Hypertension 1993, 22:178-187.
74. Spence CD, Coghlan JP, Whitworth JA, Scoggins BA: Digoxin administration enhances the pressor response to aldosterone administration in conscious sheep. Clin Exp Pharmacol Physiol 1989, 16:211-222.
75. Sekihara H, Yazaki Y, Kojima T: Ouabain as an amplifier of mineralocorticoid-induced hypertension. Endocrinology 1992, 131:3077-3082.
76. Li M, Martin A, Liu DT, Whitworth JA: Digoxin amplifies the effects of deoxycorticosterone acetate (DOCA) in intact water- drinking rats: implications for the mechanism of DOCA hypertension? J Hypertens 1994, 12:569-576.
77. Brenner BM, Garcia DL, Anderson S: The renal abnormality in hypertension: a proposed defect in glomerular filtration surface area. In Hypertension, Pathophysiology, Diagnosis, and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1990:1151-1161.
78. Chamberlain DA: The relationship of clinical effect to plasma digoxin concentration. Postgrad Med 1974, 50:29-35.
79. Lighthall GK, Manunta P, Hamlyn JM: Increased circulating ouabain i n Dahl SS/JR rats [abstract]. J Hypertens 1994, 12:5158.
80. Yamada K, Goto A, Nagoshi H, Hui C, Yagi N, Sasabe M, et al.: Participation of ouabainlike compound in reduced renal mass- saline hypertension. Hypertension 1994, 23 (suppl I):I110-113.
81. Gomez-Sanchez EP, Gomez-Sanchez CE, Fort C: Immunization of Dahl SS/Jr rats with an ouabain conjugate mitigates hypertension. Am J Hypertens 1994, 7:591-596.
82. Strobach H, Wirth KE, Rojsathapom K: Absorption, metabolism and elimination of strophanthus glycosides in man. Am J Hypertens 1994, 7:591-596.
83. Overbeck HW: Elevated arterial pressure, vascular wall waterlogging and impaired cardiac growth in rats chronically receiving digoxin. Proc Soc Exp Biol Med 1981, 167:506-513.
84. Overbeck HW, Pamnani MB, Ku DD: Arterial wall waterlogging accompanying chronic digoxin treatment in dogs. Proc Soc Exp Biol Med 1080, 164:401-404.
85. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM: Chronic reversible hypertension in rats induced by ouabain but not digoxin [abstract]. Hypertension 1992, 20 (suppl 3):404.
86. Abarquez RF: Digitalis in the treatment of hypertension, a preliminary report Acta Medics Philippina 1967, Series 2, 3:161-170.
87. Kojima I, Yoshihara S, Ogata E: involvement of endogenous digitalis-like substance In genesis of deoxycorticosterone-salt hypertension. Life Sci 1982, 30:1775-1781.
88. Yamada H, Naruse M, Naruse K, Demura H, Takahashi H, Yoshimura M, et al.: Histological study on ouabain immunoreactivity in the mammalian hypothalamus. Neurosci Lett 1992, 141:143-146.
89. Goodlin RC: Antidigoxin antibodies in eclampsia. N Engl J Med 1988, 318:518-519.
90. Kunes J, Stolba P, Pohlova I, Jelinek J, Zicha J: The importance of endogenous digoxin-like factors in rats with various forms of experimental hypertension. Clin Exp Hypertens 1985, 7:707-720.
91. Huang CT, Smith RM: Lowering of blood pressure an chronic aortic coarctate hypertensive rats with digoxin antiserum. Life Sci 1984, 35:115-118.
92. Mann JFE, Miemitz R, Ganten U, Ritz E: Haemodynamic effects of intact digoxin antibody and its Fab fragments in experimental hypertension. J Hypertens 1987, 5:543-549.
93. Balzan S, Montali U, Biver P, Ghione S: Digoxin-binding antibodies reverse the effect of endogenous digitalis-like compounds on Na,K-ATPase in erythrocytes. J Hypertens 1991, 9 (suppl 6) :S304-S305.
94. Soldin SJ, Papanastasiou-Diamandi A, Heyes J, Lingwood C, Olley P: Are immunoassays for digoxin reliable? Clin Biochem 1984, 17:317-320.
95. Masugi F, Ogihara T, Sakaguchi K, Tomii A, Hasegawa T, Chen Y, et al.: Purification and properties of a plasma ouabain-like inhibitor of Na,K-ATPase in patients with essential hypertension. J Hypertens 1988, 6:S351-S353.
96. Szalay KS: Ouabain - a local paracrine aldosterone synthesis regulating hormone. Life Sci 1993, 52:1777-1780.
97. Laredo J, Hamilton BP, Hamlyn JM: Secretion of endogenous ouabain from bovine adrenocortical cells: role of the zona glomerulosa and zona fasciculata. Biochem Biophys Res Commun 1995, 212:487-493.
98. Ludens JH, Clark MA, Robinson FG, DuCharme DW: Rat adrenal cortex is a source of circulating ouabainlike compound. Hypertension 1992, 19:721-724.
99. Laredo J, Hamlyn JM: Modulation of the release of endogenous ouabain from human adrenal CRL 7050 cells by peptidergic and non-peptidergic secretagogues [abstract]. In Proceedings of the 74th Annual Endocrine Society Meeting, San Antonio, Texas. 1992:71.
100. Cayosa LB, Hamilton BP, Manunta BP, Hagen AS, Laredo J, Hamlyn JM: Effect of ACTH and angiotensin II on plasma ouabain [abstract]. J Hypertens 1994, 12:8164.
101. Powis DA: Cardiac glycosides and autonomic neurotransmission. J Autonom Pharmacol 1983, 3:127-154.
102. Jacomini LCL, Elghozi JL, Dagher G, Devynck MA, Meyer P: Central hypertensive effect of ouabain in rats. Arch Int Pharmaodyn Ther 1984, 267:310-318.
103. Garan H, Smith TW, Powell WJ Jr: Mechanism of vasoconstrictor effect of digoxin in coronary and skeletal muscle circulation. Fed Proc 1973, 32:718.
104. Jandhyala BS, Horn G, Kivlighn SD: Studies on the role of intracellular sodium and calcium in the centrally mediated pressor effects of CSF [Na], ouabain and angiotensin II in anesthetized dogs. Clin Exp Hypertens [A] 1985, 7:793-897.
105. Shah J, Jandhyala BS: Role of Na,K-ATPase in the centrally mediated hypotensive effects of potassium in rats. J Hypertens 1991, 9:167-171.
106. Shah J, Jandhyala BS: Physiological significance of Na/K- ATPase activity in the central nervous system and endogenous sodium pump inhibitors in the neural regulation of arterial blood pressure. J Cardiovasc Pharmacol 1993, 22 (suppl 2):S13-S15.
107. Huang BS, Huang X, Harmsen E, Leenen FHH: Chronic versus peripheral ouabain, BP and sympathetic activity in rats. Hypertension 1994, 23 (part 2): 1087-1090.
108. Ferrandi M, Minotti E, Salardi S, Floriio M, Bianchi G, Ferrari P: Ouabainlike factor in Milan hypertensive rats. Am J Physiol 1992. 263:F739-F748.
109. Yamada H, Naruse M, Naruse K, Demura H, Takahashi H, Yoshimura M, et al.: Histological study on ouabain immunoreactivity in the mammalian hypothalamus. Neurosci Lett 1992, 141:143-146.
110. Guo GB, Schmid PG, Abboud FM: Effect of digoxin and amino sugar cardiac glycoside (ASI-222) on plasma antidiuretic hormone activity. J Cardiovasc Pharmacol 1982, 4:730-737.
111. Thames MD, Walkman LA, Abboud FM: Sensitization of cardiac receptors (vagal afferents) by intracoronary acetylstrophanthidin. Am J Physiol 1980, 239:H628-H635.
112. Thames MD, Miller RD, Abboud FM: Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol 1982, 243:H815-H818.
113. Ferrari A, Gregorinin L, Ferrari MC, Preti L, Mancia G: Digitalis and baroreceptor reflexes in man. Circulation 1981, 63:279-287.
114. Blaustein MP: Sodium ions calcium ions and blood pressure regulation and hypertension: an hypothesis. Am J Physiol 1977, 232:C165-C173.
115. Woolfson RG, Hilton PJ, Poston L: The effects of ouabain and low sodium on the contractility of human subcutaneous resistance vessels. Hypertension 1990, 15:583-590.
116. Woolfson RG, Poston L: Effect of ouabain on endothelin- dependent relaxation of human resistance arteries. Hypertension 1991, 17:619-625.
117. Lang S, Blaustein MP: The role of the sodium pump in the control of vascular tone. Circ Res 1980, 46:463-470.
118. Aalkjr C, Mulvany MJ: Effect of ouabain on tone, membrane potential and sodium efflux compared with 3H-ouabain binding in rat resistance vessels. J Physiol 1985, 362:215-231.
119. Songu-Mize E, Vassallo D, Rashed SSK, Varner K: Very low concentrations of ouabain enhance the phenylephrine-induced contractions in normotensive and hypertensive rat tail arteries [abstract]. Hypertension 1994, 24:384.
120. Weiss DN, Podberesky DJ, Heidrich J, Blaustein MP: Nanomolar ouabain augments caffeine-evoked contractions in rat arteries. Am J Physiol 1993, 265:C1443-C1448.
121. Kimura K, Manunta P, Hamilton BP, Hamlyn JM: Augmented contractility of the renal artery in ouabain-induced hypertension [abstract]. J Hypertens 1994, 12:8158.
122. Tyzack J, Manunta P, Hamilton BP, Hamlyn JM: Ouabain: a new endocrine factor in hypertension [abstract]. In Abstracts of the 75th Endocrine Society Meeting, Las Vegas, Nevada. 1992;377.
123. Leenen FHH, Huang BS, Yu H, Yuan B: Brain 'ouabain' mediates sympathetic hyperactivity in heart failure [abstract]. Hypertension 1995, 26:558.
124. Yamada K, Goto A, Omata M: Modulation of the levels of ouabain-like compound by central catecholamine neurons in rats. FEBS Lett 1995, 360:67-69.
125. Sawchenko PE: Effects of catecholamine depleting medullary knife cuts on CRF and vasopressin immunoreactivity in the hypothalamus of normal and steroid manipulated rats. Neuroendocrinology 1988, 48:459-470.
126. Szafarczyk A, Guillaume V, Conte-Devoix B, Alonso G, Malaval F, Pares-Herbute N, et al.: Central catecholaminergic system stimulates secretion of CRH at different sites. Am J Physiol 1988, 255:E463-E468.
127. Manunta P, Hamilton BP, Pruce E, Hamlyn JM: High dietary sodium raises plasma levels of ouabain in normal man [abstract]. J Hypertens 1992, 10 (suppl 4):S96.
128. Fujita T, Ito Y: Salt loads attenuate potassium-induced vasodilation of forearm vasculature in humans. Hypertension 1993, 21:772-778.
129. Oparil S, Chen Y-F, Meng O, Yang RH, Jin H, Wyss JM: The neural basis of salt sensitivity in the rat: altered hypothalamic function. Am J Med Sci 1988, 295:360-362.
130. Folkow B, Ely DL: dietary sodium effects on cardiovascular and sympathetic neuroeffector functions as studied in various rat models. J Hypertens 1987, 5:383-395.
131. Leenen FHH, Harmsen E, Yu H, Ou C: Effects of dietary sodium on central and peripheral ouabain-like activity in spontaneously hypertensive rats. Am J Physiol 1993, 264:H2051-H2055.
132. Yamada K, Goto A, Nagoshi H, Hui C, Omata M: Role of brain ouabainlike compound in central nervous system-mediated natriuresis in rats. Hypertension 1994, 23:1027-1031.
133. Haddy FJ, Overbeck H: The role of humoral agents in volume expanded hypertension. Life Sci 1976, 19:935-948.
134. Blaustein MP, Hamlyn JM: Pathogenesis of essential hypertension: a link between dietary salt and high blood pressure. Hypertension 1991, 18 (suppl 5) :III184-III195.
135. Hansen J: Blood volume and exchangeable sodium in essential hypertension. Acta Med Scand 1968, 184:517-523.
136. Ibsen H, Leth A: Plasma volume and extracellular fluid volume in essential hypertension. Acta Med Scand 1973, 194:93-96.